{"count":5,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/4150fb21-6764-4629-a6d9-ed58dd4a4200/","filing_uuid":"4150fb21-6764-4629-a6d9-ed58dd4a4200","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4150fb21-6764-4629-a6d9-ed58dd4a4200/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-07-17T10:20:36-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/94addd4b-8682-491e-9a08-533b05691f2a/","filing_uuid":"94addd4b-8682-491e-9a08-533b05691f2a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/94addd4b-8682-491e-9a08-533b05691f2a/print/","filing_document_content_type":"text/html","income":null,"expenses":"80000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Daniel Skallman","dt_posted":"2026-07-18T15:01:38-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1899 Pennsylvania Ave, NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401104645,"url":"https://lda.gov/api/v1/registrants/401104645/","house_registrant_id":null,"name":"CEPI-U.S.","description":"Advocacy and education on behalf of CEPI Norway","address_1":"1901 Pennsylvania Ave, NW","address_2":"Suite 1003","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DANIEL SKALLMAN","contact_telephone":"+1 202-809-6763","dt_updated":"2026-07-27T16:24:38.997168-04:00"},"client":{"id":202185,"url":"https://lda.gov/api/v1/clients/202185/","client_id":12,"name":"CEPI-U.S.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-05-24"},"lobbying_activities":[{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"Education and advocacy supporting the funding and mission of the Coalition for Epidemic Preparedness Innovations (CEPI), including development of vaccines and other countermeasures for emerging diseases to help prevent and respond to epidemics and pandemics and strengthen global health security. H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027, Title III, provisions relating to global health programs and global health security. Senate Department of State, Foreign Operations, and Related Programs Appropriations Act, 2027, Title III, provisions relating to global health programs and global health security (no bill number available as of filing).","foreign_entity_issues":"The Coalition for Epidemic Preparedness Innovations (CEPI) is based in Norway, and its mission is to promote the development and availability of vaccines and other countermeasures against emerging epidemic and pandemic diseases. Lobbying efforts by CEPI-U.S. will support that mission.","lobbyists":[{"lobbyist":{"id":112566,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"SKALLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":203,"name":"Overseas Private Investment Corp (OPIC)"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Education and advocacy supporting the funding and mission of the Coalition for Epidemic Preparedness Innovations (CEPI), including development of vaccines and other countermeasures for emerging diseases to help prevent and respond to epidemics and pandemics and strengthen global health security. H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027, Title III, provisions relating to global health programs and global health security. Senate Department of State, Foreign Operations, and Related Programs Appropriations Act, 2027, Title III, provisions relating to global health programs and global health security (no bill number available as of filing). H.R. 9260, Labor, Health and Human Services Appropriations Act, 2027, provisions related to global health programs and global health security. S. 2587, Labor, Health and Human Services Appropriations Act, 2027, provisions related to global health programs and global health security. H.R. 9150, Defense Appropriations Act, 2027, provisions related to global health programs and global health security. S. 2881, Defense Appropriations Act, 2027, provisions related to global health programs and global health security.","foreign_entity_issues":"The Coalition for Epidemic Preparedness Innovations (CEPI) is based in Norway, and its mission is to promote the development and availability of vaccines and other countermeasures against emerging epidemic and pandemic diseases. Lobbying efforts by CEPI-U.S. will support that mission.","lobbyists":[{"lobbyist":{"id":112566,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"SKALLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS","contribution":"80000.00","ownership_percentage":"100.00","address":"Skoyen Atrium, Askekroken 11, 0277","city":"Oslo","state":null,"state_display":null,"country":"NO","country_display":"Norway","ppb_city":"Oslo","ppb_state":null,"ppb_state_display":null,"ppb_country":"NO","ppb_country_display":"Norway"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d62aa936-48c3-41bf-806c-32fde9f84abf/","filing_uuid":"d62aa936-48c3-41bf-806c-32fde9f84abf","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/d62aa936-48c3-41bf-806c-32fde9f84abf/print/","filing_document_content_type":"text/html","income":null,"expenses":"60000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Cordelia Walz","dt_posted":"2026-07-20T16:42:26-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"529 14th Street NW, Suite 550","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20045","registrant":{"id":401110468,"url":"https://lda.gov/api/v1/registrants/401110468/","house_registrant_id":77481,"name":"PARKINSON'S FOUNDATION","description":null,"address_1":"529 14th Street NW, Suite 550","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20045","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CORDELIA WALZ","contact_telephone":"+1 646-974-7209","dt_updated":"2026-07-23T15:40:47.764419-04:00"},"client":{"id":71814,"url":"https://lda.gov/api/v1/clients/71814/","client_id":71814,"name":"PARKINSON'S FOUNDATION","general_description":"Non profit focused on improving care and advancing research towards a cure for Parkinson's","client_government_entity":null,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-03-17"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Increased funding for Parkinson's related programs. H.R.7148, the Consolidated Appropriations Act of 2026 and FY 2027 Appropriations bills, including funding requests for Parkinson's research and programs within: H.R.9495, the Department of Defense within the FY 2027 Department of Defense Appropriation bill. H.R.9260, the National Institute of Health and Centers for Disease Control and Prevention within the FY 2027 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.8646, the Food and Drug Administration within the FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8469, the Department of Veterans Affairs within the FY 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. H.R.9171, the Agency for Toxic Substances and Disease Registry Funding within the FY 2027 Interior, Environment, and Related Agencies Appropriations bill. OMB-2026-0034, Regulation for Federal Financial Assistance, the Office of Management and Budget's rule that revises guidance for federal funding, grants, cooperative agreements, and other forms of assistance.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Parkinson's health issues including research, care, data, costs, and accessibility of treatments. Parkinson's related programs at the Department of Health and Human Services, Food and Drug Administration, National Institutes of Health, Centers for Disease Control and Prevention. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). H.R.9233, the Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act S.1565 | H.R.138, the Lowering Costs for Caregivers Act S.3607 | H.R.6280, the Access to Genetic Counselor Services Act of 2026","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Efforts to reduce toxic exposures that are risk factors for Parkinson's, including Trichloroethylene (TCE) and paraquat. Banning paraquat, which is a risk factor for Parkinson's, and supporting the Environmental Protection Agency's reevaluation of its safety. H.R.9233, the Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act H.R. 9171, language banning paraquat within the FY 2027 Interior, Environment, and Related Agencies Appropriations bill. H.R.9357, Paraquat Prevention Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Efforts to reduce toxic exposures in agriculture settings that are risk factors for Parkinson's, including Trichloroethylene (TCE) and paraquat. Banning paraquat, which is a risk factor for Parkinson's, and supporting the Environmental Protection Agency's reevaluation of its safety. H.R.7567, the Farm, Food, and National Security Act of 2026. Proposed pesticide preemption provisions that would impact the ability of state and local governments to take action to protect human health. H.R. 9171, language banning paraquat within the FY 2027 Interior, Environment, and Related Agencies Appropriations bill. H.R.9357, Paraquat Prevention Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Parkinson's related programs at the Department of Veterans Affairs. H.R.8469, the Department of Veterans Affairs within the FY 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. H.R. 9150, the Boxing Therapy for Parkinson's Access Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Parkinson's health issues related to Medicare/Medicaid coverage and accessibility. CMS implementation of Public Law 119-21 on work requirements, including the definition of medical frailty.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d0713f03-58a0-4530-af86-49449d2e71bc/","filing_uuid":"d0713f03-58a0-4530-af86-49449d2e71bc","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/d0713f03-58a0-4530-af86-49449d2e71bc/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-10-19T10:17:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Opposition to OMB-2026-0034, Regulation for Federal Financial Assistance, which would make broad changes to the Uniform Guidance governing federal grants and cooperative agreements across federal agencies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4a4614e2-cd6b-4c95-8f3c-5e1156586e87/","filing_uuid":"4a4614e2-cd6b-4c95-8f3c-5e1156586e87","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/4a4614e2-cd6b-4c95-8f3c-5e1156586e87/print/","filing_document_content_type":"text/html","income":null,"expenses":"240000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Cordelia Walz","dt_posted":"2026-10-20T10:17:12-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"529 14th Street NW, Suite 550","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20045","registrant":{"id":401110468,"url":"https://lda.gov/api/v1/registrants/401110468/","house_registrant_id":77481,"name":"PARKINSON'S FOUNDATION","description":null,"address_1":"529 14th Street NW, Suite 550","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20045","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CORDELIA WALZ","contact_telephone":"+1 646-974-7209","dt_updated":"2026-07-23T15:40:47.764419-04:00"},"client":{"id":71814,"url":"https://lda.gov/api/v1/clients/71814/","client_id":71814,"name":"PARKINSON'S FOUNDATION","general_description":"Non profit focused on improving care and advancing research towards a cure for Parkinson's","client_government_entity":null,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-03-17"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Parkinson's health issues including research, care, data, costs, and accessibility of treatments. Parkinson's related programs at the Department of Health and Human Services, Food and Drug Administration, National Institutes of Health, Centers for Disease Control and Prevention. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66). H.R. 7779, the Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act S.1565 | H.R.138, the Lowering Costs for Caregivers Act S.3607 | H.R.6280, the Access to Genetic Counselor Services Act of 2026","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Efforts to reduce toxic exposures that are risk factors for Parkinson's, including Trichloroethylene (TCE) and paraquat. Banning paraquat, which is a risk factor for Parkinson's, and supporting the Environmental Protection Agency's reevaluation of its safety. H.R. 7779, the Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act. H.R. 9171, language banning paraquat within the FY 2027 Interior, Environment, and Related Agencies Appropriations bill. H.R.9357, Paraquat Prevention Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Increased funding for Parkinson's related programs. FY 2027 Appropriations bills, including funding requests for Parkinson's research and programs within. H.R.9495, the Department of Defense within the FY 2027 Department of Defense Appropriation bill. H.R.9260, the National Institute of Health and Centers for Disease Control and Prevention within the FY 2027 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill. H.R.8646, the Food and Drug Administration within the FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill. H.R.8469, the Department of Veterans Affairs within the FY 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. H.R.9171, the Agency for Toxic Substances and Disease Registry Funding within the FY 2027 Interior, Environment, and Related Agencies Appropriations bill. OMB-2026-0034, Regulation for Federal Financial Assistance, the Office of Management and Budget's rule that revises guidance for federal funding, grants, cooperative agreements, and other forms of assistance.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Efforts to reduce toxic exposures in agriculture settings that are risk factors for Parkinson's, including Trichloroethylene (TCE) and paraquat. Banning paraquat, which is a risk factor for Parkinson's, and supporting the Environmental Protection Agency's reevaluation of its safety. H.R.7567, the Farm, Food, and National Security Act of 2026. Proposed pesticide preemption provisions that would impact the ability of state and local governments to take action to protect human health. H.R. 9171, language banning paraquat within the FY 2027 Interior, Environment, and Related Agencies Appropriations bill. H.R.9357, Paraquat Prevention Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Parkinson's related programs at the Department of Veterans Affairs, including the Parkinson's Disease Research, Education and Clinical Centers (PADRECCs) and VA Neurology Centers of Excellence. H.R.8469, the Department of Veterans Affairs within the FY 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill. H.R. 9150, the Boxing Therapy for Parkinson's Access Act. Implementation of the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Parkinson's health issues related to Medicare/Medicaid coverage, accessibility, and remote monitoring. CMS implementation of Public Law 119-21 on work requirements, including the definition of medical frailty. CMS-1848-P, Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program. This rule would make changes to CMS's remote monitoring policy. CMS-1850-P, Calendar Year 2027 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule, a proposed rule which would expand the hospital outpatient department prior authorization process to additional botulinum toxin injection service.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Parkinson's disease-related and general medical/disease research funding and clinical trials. OMB-2026-0034, Regulation for Federal Financial Assistance, the Office of Management and Budget's rule that revises guidance for federal funding, grants, cooperative agreements, and other forms of assistance. H.R. 3521 | S. 4440, Clinical Trial Modernization Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Clinical trials, medication affordability, and medication access for people with Parkinson's. H.R. 3521 | S. 4440, Clinical Trial Modernization Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"H1-B visa rules that affect the health care workforce, physician shortages, and physician recruitment and retainment. These issues impact accesses to care for people with Parkinson's. DHS RIN 1615-AD20 / Docket No. USCIS-2026-0298: Fee for Certain H1-B Petitions, which would impose a fee for all H-1B cap-subject petitions, including those eligible for the advanced degree exemption.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153166,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"O'QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}